2019 Year in Review by President & CEO Matt Likens
As we embark on 2020, I find myself reflecting on the incredible growth GT Medical Technologies has experienced during the past year. We are filled with optimism knowing that each milestone along our journey represents new hope for patients with brain tumors.
2019 SCIENTIFIC AND BUSINESS ACHIEVEMENTS
- Completing our $10 Million Series A financing for commercialization
- Publishing the meningioma data subset in the prestigious Journal of Neurosurgery
- Winning the AZ Bio Fast Lane Award for achievements in 2018 and 2019
- Receiving 2 Best Abstract Awards for presentations on GammaTile® 5-year clinical study data at the American Association of Neurological Surgery (AANS) Annual Meeting and the American Brachytherapy Society (ABS) Annual Meeting
- Growing the GT Medical Technologies team to 15 while leveraging a skilled network of consultants
- Placing our first direct sales representatives in the field, working closely with a nationwide network of experienced distributor agents
- Began limited market release in January 2019, resulting in:
- 11 adopting institutions
- Over $1 Mil in revenue
Our team remains dedicated to elevating the standard of care for patients with brain tumors. We’ve only just begun to make an impact in the lives of patients and their families.
UPCOMING MILESTONES IN 2020
- Expanding our FDA indication to include “Newly Diagnosed Malignant and Recurrent Intracranial Neoplasms”, which more than triples the U.S. population of patients who may be candidates for GammaTile Therapy
- Transitioning from limited market release to full market release in early March
- Working towards 5X growth in sales revenue
- Building more robust clinical evidence by initiating 3 clinical studies in partnership with adopting institutions
- Gaining acceptance of 3 clinical publications with nationally-recognized journals
- Continued optimization of the manufacturing process
- Exhibiting at major national brain tumor treatment meetings, including AANS, AAPM, CNS, and ASTRO
We appreciate your continued commitment as we work toward improving the lives of patients with brain tumors.
Customer comments
No comments were found for 2019 Year in Review by President & CEO Matt Likens. Be the first to comment!